Senseonics Holdings 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Senseonics reported 3rd quarter 2026 revenue of $19.6 million, up approximately 140% from $8.1 million in the 3rd quarter of 2025, with U.S. revenue of $16.8 million and revenue outside the U.S. of $2.8 million.
- Revenue for the first 9 months of the year was $45.8 million, up approximately 118% from $21 million in the same period last year.
- Gross profit was $12.1 million, or approximately 62% gross margin, compared with $3.5 million and approximately 43% gross margin in the 3rd quarter of 2025; bundled pay represented approximately 65% of volume versus the usual roughly 60/40 split with DME.
- Research and development expenses were $11.7 million, compared with $7.8 million in the prior-year period, reflecting Gemini clinical trial activity, Freedom development, and continued Eversense 365 development.
- Selling, general, and administrative expenses were $32.3 million, compared with $15.3 million in the prior-year period; the Ascensia transition service agreement was wound down as of quarter end.
- Net loss was $32.7 million, or $0.50 per share, compared with a net loss of $19.5 million, or $0.43 per share, in the 3rd quarter of 2025.
- At September 30th, 2026, cash, cash equivalents, restricted cash, and short-term investments totaled $126.6 million; debt carrying value under the Hercules Capital facility was approximately $56.2 million, with $55 million in principal borrowings outstanding.
- Management reported record shipment volume and new patient starts, active prescribers up over 90% year over year, approximately 9 out of 10 new insertions from patients switching from a competitive sensor, and an annual reorder rate ahead of expectations.
- EonCare exceeded its year-end goal of 100 inserters during the 3rd quarter; Senseonics now expects approximately 120 inserters by year-end, and Eon accounted for over 40% of U.S. Eversense insertions in the quarter.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please note, today's call will be recorded. I will be standing by should you need any assistance. It is now my pleasure to turn the conference over to Jeremy Feffer from LifeSci Advisors. Please go ahead. Thank you.
This is Jeremy Feffer from LifeSci Advisors. Before we begin today, let me remind you that the company's remarks include forward-looking statements. These statements reflect management's expectations about future events, operating plans, regulatory matters, product enhancements, company performance, and other matters, and speak only as of the date hereof. These forward-looking statements involve a number of risks and uncertainties. A list of the factors that could cause actual results to be materially different from those expressed or implied by any of these forward-looking statements is detailed under risk factors and elsewhere in our annual report on Form 10-K for the year ended December 31, 2025, our 10-Q for the period ended September 30, 2026, and our other reports filed with the SEC. These documents are available on the investor relations section of our website at www.senseonics.com.
We undertake no obligation to update publicly or revise these forward-looking statements for any reason, except as required by law. Joining me today from Senseonics are Tim Goodnow, President and Chief Executive Officer, Brian Hansen, Chief Commercial Officer, and Rick Sullivan, Chief Financial Officer. Mukul Jain, Chief Operating Officer, will also be available during the Q&A. Now, I'd like to turn the call over to Tim.
Thanks, Jeremy, and good afternoon, everyone. Q3 was a breakout quarter for Senseonics. Revenue reached $19.6 million, up about 140%, well more than double the prior year. It's the highest in our history, and the second quarter in a row in which we have set a new mark. This is driven by a record number of new patient starts. In the U.S., revenue grew about 160% to $16.8 million, and outside the U.S., it rose about 65% to $2.8 million. Our sales are running ahead of our earlier expectations, and we are now raising full-year revenue guidance for the third time this year. We are now projecting $68 million-$70 million of full-year revenue from our prior range of $62 million-$66 million. What's driving this? First and foremost, the product.
Eversense 365 is the only CGM that delivers a full year on a single sensor with exceptional accuracy throughout and a removable transmitter that is easy on the skin. Patients feel the difference, and retention is exceeding our plan. Our execution is amplifying these advantages, and our commercial team is performing superbly. Together, we are making Eversense easier to get. Our insertion network keeps widening, reimbursement is improving, and our integration partnerships are growing. Those are the priorities we set at the start of the year, and each one is delivering. Just as telling is where our new patients are coming from. The overwhelming majority are switching from other CGMs. Millions of people are on short-term sensors, and when they see what our year-long sensor can do, a growing number are choosing Eversense 365. This is a large opportunity, and we are only beginning to tap it.
Pump compatibility is another accelerant. The twiist integration with Sequel shows what is possible. The first year with twiist has been fantastic. in September, we announced another partnership, this time with Beta Bionics, which will pair Eversense 365 with the iLet Bionic Pancreas. The teams are working closely, and commercial launch is expected in the coming weeks, with first patients possible before year-end and an additional source of growth in 2027. Beyond the iLet, we plan to keep working side by side to have Eversense 365 integrated with the mint system as it comes to market. Then there is Freedom. on October 26th, we began human testing of what is designed to be the world's first CGM with no on-body component. Picture a full year of glucose data with nothing to wear, invisible monitoring.
Eliminating the transmitter is one of the biggest differentiators in CGM and the improvement people ask for most. We are not just leading the race to deliver it, we are the only company with the technology, the experience, and the reach to get it done. We know Freedom will be truly revolutionary product for our space. Freedom builds on the proven sensing technology behind Eversense 365, adding an integrated battery, which we have studied in our ongoing Gemini studies with embedded Bluetooth capability. Preclinical work guided our choice of antenna, system design, and architecture, and now we are learning how it performs in people. The first in-human study is an early feasibility evaluation. It looks at the safety and device function, including the direct Bluetooth communication in the real world to inform our pivotal study, which we expect to start in 2027.
We are targeting the potential launch of the Freedom system in 2028, and advancing this program is our top priority for our development efforts. Taken together, today we have a business growing at a remarkable pace, another pump launch weeks away, and a pipeline built to redefine what a CGM can be. We are well-positioned to further this momentum into 2027. For more detail, Brian will speak to our commercial progress, and Rick will follow with the financials and our updated outlook.
Brian? Thanks, Tim, and good afternoon, everyone.
At the beginning of the year, we identified patient access, reimbursement, pump partnerships, and user retention as key priorities for our commercial program. We are making progress across each of these areas, and that execution is supporting our growth. Fueled by our initiatives in these areas, we reported record shipment volume and a record number of new patient starts in the third quarter. Driving this performance is our experienced commercial team. We've seen little change over the past year, and the team's experience and continuity are helping us strengthen relationships with prescribers and improve coordination with our patient support and insertion networks. As the business grows, we expect to gain further productivity from the team and the infrastructure that we have put in place while adding resources selectively to support this demand. Direct-to-consumer advertising remains our largest source of new patient starts.
The majority of our DTC conversion metrics improved again in the third quarter, with several reaching their best levels to date. We continue to invest in this channel, and as our experience grows, refine how we move patients from initial interest to insertion. Our healthcare provider channel is also becoming more productive as our sales team deepens account relationships and awareness of Eversense 365 expands. Active prescribers also reached a new record, up over 90% year-over-year. Together, these channels are helping us reach more patients and convert that interest into more new starts. A couple of underlying metrics continue to give us confidence in the durability of the growth we have been seeing. First, our annual reorder rate remains ahead of where we expected it to be at this point in the product's life cycle.
We also continue to see approximately nine out of 10 new insertions come from patients switching from a competitive sensor. Both factors speak to just how differentiated the Eversense 365 experience is once patients and providers get to see it firsthand, which we believe bodes well for continued growth. Our partnership with Sequel and the integration with the twiist pump continues to perform well for us. We are encouraged by the uptake of the Eversense 365 alongside twiist and the positive feedback from patients, healthcare providers, and our partner. This experience supports our view that pump compatibility can bring additional patients to Eversense, opening the door to those in the U.S. who want an AID solution. The Beta Bionics relationship Tim just described builds on that opportunity, with initial adoption expected following launch this quarter. We expect this expansion of AID choice to support continued Eversense growth in 2027.
Choice is important in diabetes care, and we remain focused on expanding the options available to patients and their healthcare providers. Turning to EON Care, the network continues to scale ahead of plan. During the third quarter, we already surpassed our year-end goal of 100 inserters and now expect to reach approximately 120 inserters by year-end. EON performed a record number of insertions in the quarter, accounting for over 40% of all Eversense insertions in the United States. We are pleased with how the network simplifies and expands access for interested patients. EON makes it easier for healthcare providers to prescribe Eversense without performing the insertion themselves and helps connect more patients coming through the DTC channel with a qualified insertion provider. The network also supports our geographic expansion.
As we add inserters in previously unserved areas, we can extend our advertising and commercial efforts into those markets with an insertion option already in place. Briefly on Europe, revenue outside the U.S. was $2.8 million in the quarter, up approximately 65% year-over-year. The transition of the commercial teams from Ascensia is complete, and our dedicated teams are leading the Eversense 365 launches in Germany, Italy, Spain, and Sweden. With our commercial operations now fully integrated into Senseonics globally, we are focused on building adoption and expanding patient access across these markets. With that, I will turn it over to Rick to walk through our financial results.
Thanks, Brian, and thanks, everyone, for joining us this afternoon. I will walk you through our financial results for the third quarter and provide an update to our full-year guidance. Net revenue for the third quarter was $19.6 million, an increase of approximately 140% compared to $8.1 million in the third quarter of 2025. U.S. revenue was $16.8 million, up approximately 160% from $6.4 million in the prior year period, and revenue outside the U.S. was $2.8 million, up approximately 65% from $1.7 million in the third quarter of 2025. Through the first nine months of the year, total revenue was $45.8 million, up approximately 118% from $21 million in the same period last year. Gross profit for the third quarter of 2026 was $12.1 million, representing a gross margin of approximately 62%, compared to gross profit of $3.5 million, or approximately 43% gross margin for the third quarter of 2025.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
11 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
